Johnson & Johnson Reports New Clinical Data for VARIPULSE and OMNYPULSE Platforms

Johnson & Johnson presented new clinical data for its electrophysiology portfolio at the Asia Pacific Heart Rhythm Society (APHRS) 2026 meeting. The company reported the first real-world data for its VARIPULSE Pro Platform, a pulsed field ablation technology, and shared 12-month clinical outcomes for its OMNYPULSE Platform used in atrial fibrillation treatment. These developments underscore the company's commitment to enhancing its medical technology offerings in the cardiovascular sector.